BACE1 and Alzheimer disease: One month of oral administration of RA-PR058 significantly alleviated anxiety-like behavior, decreased BACE1 expression, and reduced tau phosphorylation at AD-related sites, including Ser202/Thr205 (AT8), Thr231 (AT180), and Ser396.